Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Latest Advances in PDX Modelling for Oncology Drug Discovery

Published: Friday, September 13, 2013
Last Updated: Friday, September 13, 2013
Bookmark and Share
PRECOS' co-presentation with Crown Bioscience from Tumor Models Boston 2013 meeting available for download.

Preclinical Oncology Services Limited (PRECOS) has announced the availability of its co-presentation with Crown Bioscience delivered at the Tumor Models Boston 2013 meeting.

The presentation highlights the application of human surrogate trials to oncology drug discovery and how a comprehensive panel of PDX (Patient-Derived Xenograft) models of cancer can help better predict the effectiveness of drugs in clinical trials.

Historically the oncology drug development process is slow, expensive, inefficient and ultimately unsustainable. PRECOS and Crown Bioscience recognize the need to bring clinical decision-making earlier into the process.

Dr Aaron Cranston, Head of in vivo services, PRECOS Ltd comments, “Translating oncology drug discovery into improved patient outcome is the fundamental mission for both PRECOS and Crown Biosciences. By using human surrogate trials (HuTrials®) it is possible to identify biomarker signatures of patient responders and non-responders following treatment with targeted agents, reduce the attrition rate of new chemical entities (NCEs) in the clinic, accelerating drug development and improve chances of translational success.

By focusing on developing tumor models that are truly representative of patient outcomes, PRECOS and Crown Biosciences enable drug developers to overcome the challenges faced in preclinical oncology when testing new cancer drugs.

Problems in oncology drug development include a failure to consistently deliver highly effective drugs to patients, with many new drugs providing incremental benefit at non-incremental costs.

The ultimate goal in the oncology community is effective drug performance in the clinic and PDX models are superior in predicting efficacy and mimicking tumour activity in patients.

Also known as tumor graft models, PDXs are based on the transfer of primary tumors directly from the patient into an immunodeficient mouse.

PRECOS presented alongside its parent company Crown Bioscience on the latest developments in PDX modelling, highlighting the scale and skill of Crown Bioscience’s resources to maintain hundreds of in vivo PDX models in simultaneous passage ready for screening.

The presentation illustrates how PDX are being used today to discover biomarkers and run human surrogate trials using the world’s most comprehensive commercially available PDX collection.

The presentation is available to download via www.precos.co.uk/publications/ or email precos@scottpr.com to request a copy.

Dr Cranston continues, “PRECOS is committed to developing improved preclinical models and providing researchers with the very best oncology tools for superior predictions, which will ultimately lead to enhanced patient response. Molecular profiling and characterization underpins the models and the innovative approaches developed by PRECOS enable scientists to fast-track new agents into the clinic.”

Tumor Models 2013 was hosted in Boston from 23rd - 25th July. The meeting was attended by international researchers interested in optimizing models, exploring alternatives and predicting efficacy for enhanced clinical performance.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PRECOS Awarded HTA License and Expands PDX Drug Discovery Models
Company has been awarded license to store and research human tissue samples by the Human Tissue Authority.
Monday, August 27, 2012
PRECOS Appoints Dr Martin Page as Scientific Consultant
Appointment reinforces the ambition of PRECOS to contribute to the growing cancer therapy market.
Tuesday, February 21, 2012
PRECOS and Argenta Extend Collaboration to Offer World Class Integrated Oncology Drug Discovery Services
Five-year extension of the alliance allows both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.
Wednesday, March 23, 2011
PRECOS Doubles Capacity and Appoints New Senior Scientific Staff to Accommodate Significant Growth
The company has expanded to accommodate existing and anticipated growth in line with its leadership in oncology drug discovery.
Tuesday, February 15, 2011
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!